Radiotherapy has an established palliative role for bone metastases but despite the large number of patients treated there is still controversy surrounding the optimal radiotherapy schedule to prescribe. The aim of this survey was to determine the decision patterns of Italian radiation oncologists in four different clinical cases of patients with bone metastases.
Methods and study design
During the latest national meeting of the Italian Association of Radiation Oncology (AIRO), four clinical cases were presented to attending radiation oncologists. The cases were different with respect to the histology of the primary tumor, performance status, pain before and after analgesics, tumor site, and radiological characteristics of the metastatic lesions. For each clinical case the respondents were asked to give an indication for treatment; prescribe doses, volumes and treatment field arrangements; decide whether to prescribe prophylactic supportive therapy or not; and provide information about factors that particularly influenced prescription. Finally, a descriptive statistical analysis was performed.
Results
Three hundred questionnaires were distributed to radiation oncologists attending the congress. One hundred twenty-five questionnaires were returned but only 122 (40.6%) were adequately completed and considered for the analysis. Considerable differences were observed among radiation oncologists in prescribing and delivering radiotherapy for bone metastases. There was also a notable divergence from international guidelines, which will be discussed in this report.
Conclusions
Despite the results of clinical trials, Italian radiation oncologists differ considerably in their decisions on treatment doses and volumes. National guidelines are needed in order that patients can be treated uniformly and better data will become available for evidence-based palliative radiotherapy.
ColemanR.E., RubensR.D.: The clinical course of bone metastases from breast cancer.Br J Cancer, 55: 61–66, 1987.
2.
HoskinP.J.: Radiotherapy in the management of bone pain.Clin Orthop, 312: 105–119, 1995.
3.
FalkmerU., JarhultJ., WersallP., Cavallin-StahlE.: A systematic overview of radiation therapy effects in skeletal metastases.Acta Oncol, 42: 620–633, 2003.
4.
RoseC.M., KaganR.: The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology.Int J Radiat Oncol Biol Phys, 40: 1117–1124, 1998.
5.
TongD., GillickL., HendricksonF.R.: The palliation of symptomatic osseous metastases. final results of the study by the Radiation Therapy Oncology Group.Cancer, 50: 893–899, 1982.
6.
HartsellW.F., ScottC.B., BrunerD.W., ScarantinoC.W., IvkerR.A., RoachM3rd, SuhJ.H., DemasW.F., MovsasB., PetersenI.A., KonskiA.A., CleelandC.S., JanjanN.A., DeSilvioM.: Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.J Natl Cancer Inst, 97: 798–804, 2005.
7.
SteenlandE., LeerJ.W., van HouwelingenH., PostW.J., van den HoutW.B., KievitJ., de HaesH., MartijnH., OeiB., VonkE., van der Steen-BanasikE., WiggenraadR.G., HoogenhoutJ., Wárlám-RodenhuisC., van TienhovenG., WandersR., PompJ., van ReijnM., van MierloI., RuttenE.: The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study.Radiother Oncol, 52: 101–109, 1999.
8.
MadsenE.L.: Painful bone metastasis: Efficacy of radiotherapy assessed by the patients—A randomized trial comparing 4 Gy x 6 versus 10 Gy x 2.Int J Radiat Oncol Biol Phys, 9: 1775–1779, 1983.
9.
NiewaldM., TkoczH.J., AbelU., ScheibT., WalterK., NiederC., SchnabelK., BerberichW., KubaleR., FuchsM.: Rapid course radiation therapy vs. more standard treatment: A randomized trial for bone metastases.Int J Radiat Oncol Biol Phys, 36: 1085–1089, 1996.
10.
ShakespeareT.P., ThiagarajanA., GebskiV.: Evaluation of the quality of radiotherapy randomized trials for painful bone metastases.Cancer, 103: 1976–1981, 2005.
11.
JeremicB., ShibamotoY., AcimovicL., MilicicB., MilisavljevicS., NikolicN., AleksandrovicJ., IgrutinovicI.: A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain.Int J Radiat Oncol Biol Phys, 42: 161–167, 1998.
12.
Bone Pain Trial Working Group:8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: Randomised comparison with a multifraction schedule over 12 months of patient follow-up.Radiother Oncol, 52: 111–121, 1999.
13.
BlitzerP.H.: Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis.Cancer, 55: 1468–1472, 1984.
14.
PriceP., HoskinP.J., EastonD., AustinD., PalmerS.G., YarnoldJ.R.: Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.Radiother Oncol, 6: 247–255, 1986.
15.
WuJ.S., WongR., JohnstonM., BezjakA., WhelanT.; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group: Meta-analysis of dose fractionation radiotherapy trials for the palliation of painful bone metastases.Int J Radiat Oncol Biol Phys, 55: 594–605, 2003.
16.
SzeW.M., ShelleyM., HeldI., MasonM.: Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy – a systematic review of the randomised trials.Cochrane Database Syst Rev, 2: CD004721, 2004.
17.
RoosD.E.: Continuing reluctance to use single fractions of radiotherapy for metastatic bone pain: An Australian and New Zealand practice survey and literature review.Radiother Oncol, 56: 315–322, 2000.
18.
ChanderS.S., SarinR.: Single fraction radiotherapy for bone metastases: Are all questions answered?Radiother Oncol, 52: 191–193, 1999.
19.
CrellinA.M., MarksA., MaherE.J.: Why don't British radiotherapists give single fractions of radiotherapy for bone metastases?Clin Oncol (R Coll Radiol), 1: 63–66, 1989.
20.
FairchildA., BarnesE., GhoshS., Ben-JosefE., RoosD., HartsellW., HoltT., WuJ., JanjanN., ChowE.: International patterns of practice in palliative radiotherapy for painful bone metastases: evidence-based practice?Int J Radiat Oncol Biol Phys, 75: 1501–1510, 2009.
21.
LievensY., Van den BogaertW., RijndersA., KutcherG., KestelootK.: Palliative radiotherapy practice within Western European countries: impact of the radiotherapy financing system?Radiother Oncol, 56: 289–295, 2000.
22.
MaherE., CoiaL., DuncanG., LawtonP.A.: Treatment strategies in advanced and metastatic cancer: differences in attitude between the USA, Canada and Europe.Int J Radiat Oncol Biol Phys, 23: 239–244, 1992.
23.
van den HoutW., van der LindenY., SteenlandE., WiggenraadR.G., KievitJ., de HaesH., LeerJ.W.: Single versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial.J Natl Cancer Inst, 5;, 95: 222–229, 2003.
24.
PollicinoC., TurnerS., RoosD., O'BrienP.C.: Costing the components of pain management: analysis of Trans-Tasman Radiation Oncology Group trial (TROG 96.05): one versus five fractions for neuropathic bone pain.Radiother Oncol, 76: 264–269, 2005.
25.
KonskiA.: Radiotherapy is a cost-effective palliative treatment for patients with bone metastases from prostate cancer.Int J Radiat Oncol Biol Phys, 60: 1373–1378, 2004.
26.
SzumacherE., Llewellyn-ThomasH., FranssenE., ChowE., DeBoerG., DanjouxC., HayterC., BarnesE., AnderssonL.: Treatment of bone metastases with palliative radiotherapy: patients' treatment preferences.Int J Radiat Oncol Biol Phys, 61: 1473–1481, 2004.
27.
ShakespeareT., LuJ., BackM., LiangS., MukherjeeR.K., WynneC.J.: Patient preference for radiotherapy fractionation schedule in the palliation of painful bone metastases.J Clin Oncol, 21: 2156–2162, 2003.
28.
ChowE., DanjouxC., WongR., SzumacherE., FranssenE., FungK., FinkelsteinJ., AnderssonL., ConnollyR.: Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists.Radiother Oncol, 56: 305–314, 2000.
29.
van der LindeY., RoosD., LutzS., FairchildA.: International variations in radiotherapy fractionation for bone metastases: geographic borders define practice patterns?Clin Oncol, 21: 655–658, 2009.
30.
PergolizziS., PontorieroA., DeliaP., SantacaterinaA.: External beam irradiation in the palliation of bone metastases: a practice analysis among Sicilian departments of radiation oncology.Tumori, 90: 86–90, 2004.
31.
BradleyN.M., HustedJ., SeyM.S., HusainA.F., SinclairE., HarrisK., ChowE.: Review of patterns of practice and patients' preferences in the treatment of bone metastases with palliative radiotherapy.Support Care Cancer, 15: 373–385, 2006.
32.
RoosD.E.: Continuing reluctance to use single fractions of radiotherapy for metastatic bone pain: an Australian and New Zealand practice survey and literature review.Radiother Oncol, 56: 315–322, 2000.
33.
CoiaL.R., OwenJ.B., MaherE.J., HanksG.E.: Factors affecting treatment patterns of radiation oncologists in the United States in the palliative treatment of cancer.Clin Oncol (R Coll Radiol), 4: 6–10, 1992.
34.
MercadanteS., FulvaroF.: World Health Organisation guidelines for cancer pain: a reappraisal.Ann Oncol, 16(suppl 4): 132–135, 2005.
HartsellW.F., KonskiA.A., LoS.S., HaymanJ.A.: Single fraction radiotherapy for bone metastases: clinically effective, time efficient, cost conscious and still underutilized in the United States?Clin Oncol (Coll Radiol), 21: 652–654, 2009.
38.
PradierO., BouchekouaM., AlbargachN., MullerM., MalhaireJ.P.: How to irradiate bone metastases?Cancer Radiother, 12: 837–841, 2008.
39.
BradyL.W., PerezC.A., HalperinE.C. (Eds): Principles and practice of radiation oncology, 5th edition.Lippincott Williams & Wilkins, Philadelphia, 2007.
40.
AndicF., Baz CifciS., OrsY., NiangU., DirierA., AdliM.: A dosimetric comparison of different treatment plans of palliative spinal bone irradiation: analysis of dose coverage with respect to ICRU 50 Report.J Exp Clin Cancer Res, 28: 2, 2009.
41.
RezvoyN., DubrayB.: Probabilities of organs at risk damage: history and mathematical models.Cancer Radiother, 14: 241–245, 2010.
42.
PointreauY., KrepsS., HennequinC.: Side effects evaluation of ionizing radiation.Cancer Radiother, 14: 246–249, 2010.
43.
AzriaD., PointreauY., ToledanoA., OzsahinM.: Factors of late radiosensitivity of normal tissues.Cancer Radiother, 14: 250–254, 2010.
44.
MartinE., PointreauY., Roche-ForestierS., BarillotI.: Normal tissue tolerance to external beam radiation therapy: small bowel.Cancer Radiother, 14: 350–353, 2010.
45.
De BariB., PointreauY., RioE., MirabelX., MornexF.: Normal tissue tolerance to external beam radiation therapy: liver.Cancer Radiother, 14: 344–349, 2010.
46.
OberdiacP., MineurL.: Normal tissue tolerance to external beam radiation therapy: the stomach.Cancer Radiother, 14: 336–339, 2010.
47.
BeraG., PointreauY., DenisF., OrainI., DupuisO., CréhangeG.: Normal tissue tolerance to external beam radiation therapy: esophagus.Cancer Radiother, 14: 327–335, 2010.
48.
DoyenJ., GiraudP., BelkacemiY.: Normal tissue tolerance to external beam radiation therapy: cardiac structures.Cancer Radiother, 14: 319–326, 2010.
49.
OrtholanC., MornexF.: Normal tissue tolerance to external beam radiation therapy: lung.Cancer Radiother, 14: 312–318, 2010.
50.
BlanchardP., ChapetO.: Normal tissue tolerance to external beam radiation therapy: rectum.Cancer Radiother, 14: 354–358, 2010.
51.
PointreauY., AteanI., DurduxC.: Normal tissue tolerance to external beam radiation therapy: bladder.Cancer Radiother, 14: 363–368, 2010.
52.
BartonR., RobinsonG., GutierrezE., KirkbrideP., McLeanM.: Palliative radiation for vertebral metastases: the effect of variation in prescription parameters on the dose received at depth.Int J Radiat Oncol Biol Phys, 52: 1083–1091, 2002.
53.
MaranzanoE., FeyerP.C., MolassiotisA., RossiaR., Clark-SnowR.A., OlverI., WarrD., SchiavoneC., RoilaF., on behalf of Participants in the Perugia Consensus Conference 2004: Evidence-based recommendations for the use of antiemetics in radiotherapy.Radiother Oncol, 76: 227–233, 2005.
54.
RubensteinE.B., PetersonD.E., SchubertM., KeefeD., McGuireD., EpsteinJ., EltingL.S., FoxP.C., CooksleyC., SonisS.T.; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis.Cancer, 100 (9 Suppl): 2026–2046, 2004.
55.
SteerC.B., HarperP.G.: Gastro-oesophageal complications in patients receiving cancer therapy: the role of proton pump inhibitors.Eur J Gastroenterol Hepatol, 14(Suppl 1): S17–21, 2002.
